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Abstract Systemic sclerosis (SSc) is complicated by
pulmonary hypertension and right ventricle (RV) failure in
approximately 10% of the patients. Factors influencing the
reactivity of pulmonary circulation to vasodilators are not
established, while the examination of vasoreactivity is
important in determining the treatment, because systemic
administration of oral vasodilators can induce severe
adverse events in nonresponders. The mechanism of RV
failure in SSc is unclear and may result either from
increased RV afterload or intrinsic myocardial disease. The
aim of the study was to assess the reactivity of pulmonary
circulation to inhaled nitric oxide (iNO) and to evaluate its
influence on RV function in SSc patients with elevated right
ventricle systolic pressure (RVSP). In 60 SSc patients aged
24–73 (58 females, two males; 33 patients with limited SSc
and 27 with diffuse SSc), echocardiographic examination
with tissue Doppler echocardiography (TDE) was performed.
RV function was measured by systolic (S) and early diastolic
(E) velocity of tricuspid annulus by TDE. In patients with
RVSP >45 mmHg, the reactivity of pulmonary circulation
was assessed by iNO test. High-resolution computerized
tomography (HRCT) was performed to assess the extent
of pulmonary fibrosis. Of 14 SSc subjects with elevated
RVSP (13 females, one male; RVSP 47–62 mmHg), positive
reaction to iNO was observed in five (RVSP decreased from
51.6±3.7 to 32.24±2.3 mmHg); nine patients were not
reactive (RVSP 53.5±5.7 mmHg before iNO vs. 49.6±
6.7 mmHg). RV systolic function was decreased in patients
with elevated RVSP as compared to the patients with normal
pulmonary pressure (S velocity 13.2±1.3 vs. 14.4±1.6 cm/s,
respectively, p<0.05). Significant increase of RV systolic
function during iNO test was found in reactive patients only
(S velocity before iNO 12.8±1.2 cm/s, during iNO 14.5±
1.5 cm/s, p<0.01). RVSP decrease strongly correlated with S
velocity increase (r=0.95, p<0.0001). Response to iNO was
found only in limited form of SSc; diffuse SSc patients
showed no response. Pulmonary fibrosis on HRCT was
more frequent in subjects nonreactive to iNO (67% of
patients) than in the reactive group (40% of patients).
The reactivity of pulmonary circulation to iNO in SSc
patients with elevated RVSP was found predominantly in
limited form of the disease. Pulmonary fibrosis typical
for diffuse SSc was more frequent in nonreactive
subjects. Elevated pulmonary pressure plays an important
role in RV systolic dysfunction. Pulmonary pressure
decrease during iNO test leads to the improvement of
RV systolic function. Therapy for right-heart failure in
reactive SSc patients should be directed, if possible, at
the decrease in pulmonary resistance.
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Objective and aim of the study
Systemic sclerosis (SSc) is complicated in approximately
10% of the patients by pulmonary hypertension (PH)
caused mainly by an increase in pulmonary vascular
resistance [1]. The prognosis of SSc–PH without pulmo-
nary circulation-targeted therapies is particularly poor, with
estimated survival rates of approximately 50% at 2 years
[1]. While prostacyclin, endothelin receptor antagonists and
phosphodiestease-5 inhibitors has been shown to be
partially efficacious in PH, SSc–PH remains incurable [1].
Moreover, factors influencing reactivity of pulmonary
circulation to vasodilators seen in some patients [2] remain
unknown [3]. Their identification may be important to
make a proper choice of treatment because systemic
administration of oral vasodilators can induce severe
adverse events in nonresponders [4].
The second factor influencing prognosis in SSc patients
is cardiac involvement. While left ventricle diastolic
dysfunction plays a major role [5], recent studies based on
tissue Doppler echocardiography (TDE) has also shown
systolic and diastolic dysfunction involving right ventricle
[6, 7]. The mechanism of right ventricle dysfunction in SSc
is not completely understood: this may involve increased
right ventricle afterload caused by pulmonary hypertension
as well as SSc-specific fibrotic tissue accumulation in the
myocardium.
The aim of the study was to assess the reactivity of
pulmonary circulation to inhaled nitric oxide (iNO) and to
evaluate its influence on right ventricle function in SSc
patients with elevated right ventricle systolic pressure
(RVSP).
Material and methods
Study group consisted of 60 consecutive SSc patients (58
females, two males) aged 24–73 (mean age 54.4 years). The
diagnosis was established according to the American
College of Rheumatology standards [8]. Limited SSc was
diagnosed in 33 (55%) patients, and diffuse SSc in 27
(45%). Duration of the disease was 2–32 years (mean
15.5 years). Scl-70 autoantibodies were found in 42 (70%)
patients, anticentromere in 16 (26.7%), and other autoanti-
bodies (anti-fibrillarin, Ku, Ro, antimitochondrial) in 13
(21.7%). Arterial hypertension was present in four patients.
Dyspnea at rest was not observed in any of the patients. The
results of peripheral blood count, serum sodium, potassium,
glucose, creatinine, and urinalysis were all normal. The
patients were treated with (n, %): pentoxyfilline (42, 70%),
calcium blockers (18, 30%), cinnarizine (10, 16.7%),
nicergoline (7, 11.7%), xantinol nicotinate (10, 16.7%),
bencyclane (7, 11.7%), prednisone (8, 13.3%), angiotensin-
converting enzyme inhibitors (18, 30%), diosmine (13,
21.7%), ranitidine (8, 13.3%), and hydroxizine (13, 21.7%).
In all the subjects, echocardiographic examination
with tissue Doppler echocardiography was performed.
The data obtained form echocardiographic examination
(Toshiba Aplio SSA-770 Ultrasound System, Toshiba,
Japan) included: diastolic and systolic dimension of left
ventricle, ejection fraction of left ventricle (Simpson
method), diastolic dimension of right ventricle, thickness
of the left ventricle walls in diastole, E and A mitral inflow
velocity, valvular pressures gradients, and regurgitation
assessment. RVSP was calculated from the velocity of
tricuspid regurgitant jet (Vtr) according to the equation
RVSP ¼ 4Vtr þ RAPmmHg, where RAP represents right
atrial pressure, estimated as 5 or 10 mmHg due to inferior
vena cava and right atrium diameters. During TDE
examination, the velocities of tricuspid annulus were
recorded from four-chamber view during systole (S
velocity) and early diastole (E velocity). Isovolumetric
relaxation time (IVRT) was measured by TDE examina-
tion as the time from the end of S velocity to the onset
of E velocity.
Based on right-heart catheterization studies, a gold
standard for pulmonary artery pressure measurement,
RVSP=47 mmHg might be used as a cut-off point for PH
screening in SSc patients by means of echocardiography [9].
In our study, in patients with RVSP exceeding 45 mmHg, the
reactivity of pulmonary circulation was assessed by inhaled
nitric oxide test. However it is apparent that a significant
proportion of the hemodynamic response to iNO occurs at
concentrations below 10 ppm [4], we used the maximal dose
of iNO (40 ppm) [4]. All the aforementioned echocardio-
graphic and TDE parameters were determined in patients
during the test (after 10 min of breathing NO). Positive
reaction to iNO (reactive pulmonary circulation) was defined
as a decrease of RVSP of more than 10 mmHg during the
test. In patients with elevated RVSP, spirometry and high-
resolution computerized tomography were performed to
assess the extent of pulmonary involvement.
Statistical analysis was performed using Statistica Six
Sigma software. All numerical data were expressed as
mean values±standard deviations or as proportions.
Continuous variables were compared by use of t test.
Chi-square test was used to examine differences in
proportions. The relationship between the pulmonary
systolic pressure change and the tricuspid annulus systolic
velocity change was shown by use of linear regression
with 95% confidence intervals. The level for statistical
significance was predetermined at p<0.05.
The study was approved by the Ethical Committee.
Before the study, informed consent was obtained from
each patient. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
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Results
Echocardiographic examination showed normal left
ventricle dimensions (47.7±5.9 mm in diastole, 30.5±
7.5 mm in systole) with normal ejection fraction (67.5±
7.3%) in 58(96.7%) SSc patients. Left ventricle was
dilated (>56 mm in diastole) and ejection fraction
decreased (<55%) in two (3.3%) patients. In contrast,
mitral inflow E/A ratio was decreased (<1.0) in 38
(63.3%) patients, showing diastolic left ventricular dysfunc-
tion, that was present despite normal left ventricle muscle
thickness (intraventricular septum diastolic thickness 8.9±
1.8 mm, posterior wall diastolic thickness 8.8±1.6 mm). No
signs of significant valvular disturbances were observed,
excepting moderate tricuspid insufficiency in 21 (46%)
patients. Right ventricle was dilated (>30 mm in parasternal
view) in eight (13.3%) patients.
Among 60 examined patients, RVSP >45 mmHg was
found in 14 subjects, 13 females and one male. Left ventricle
dimensions and function were normal in this group. RVSP
values ranged from 47 to 62 mmHg (mean 53.6±4.8 mmHg).
In the remaining 46 patients, mean RVSP value was 28.2±
3.7 mmHg (ranging from 20 to 36 mmHg).
The dose of iNO (40 ppm) appeared safe and did not
result in systemic hypotension in any of the 14 patients in
which the test was performed. Out of this group, positive
reaction to iNO was observed in five patients. Their mean
pulmonary systolic pressures decreased from 51.6±3.7 to
32.24±2.3 mmHg. In the remaining nine patients, pulmo-
nary pressures did not change (53.5±5.7 mmHg before the
test, 49.6±6.7 mHg during the test; Fig. 1).
Right ventricle systolic function was decreased in patients
with RVSP elevation as compared to the patients with
normal pulmonary pressure (S velocity 13.2±1.3 vs. 14.4±
1.6 cm/s, respectively; p<0.05), diastolic right ventricle
function was comparable in both groups (E velocity 12.8±
2.2 vs. 13.4±4.2 cm/s, respectively, p>0.05). During iNO
test, significant increase of right ventricle systolic function
was found in the group of five patients with reactive
pulmonary circulation; whereas in nonreactive patients,
systolic function of right ventricle remained unchanged
(Fig. 2). Diastolic right ventricle function was not
changed in neither group (E velocity in reactive patients
12.9±1.2 cm/s before iNO, 12.7±1.7 cm/s during iNO, E
velocity in nonreactive patients 12.8±3.1 cm/s before
iNO, 13.8±1.7 cm/s during iNO).
The isovolumetric relaxation time of right ventricle
(normal values, <40 ms [10]) was significantly prolonged
in patients with RVSP >45 mmHg as compared to patients
with normal pulmonary systolic pressure (90±7.7 vs. 28±
9.4 ms, respectively, p<0.001). In subjects with reactive
pulmonary circulation, IVRT normalized from 87±5.7 to
27±11.4 ms during iNO test (p<0.001; Fig. 3); whereas in
nonreactive, subjects remained unchanged (93±8.7 ms
before iNO, 89±13.5 ms during iNO).
Strong correlation was found between the decrease in
RVSP and the increase in tricuspid annulus systolic velocity
(r=0.95, p<0.0001; Fig. 4).
The type of the disease strongly differentiated patients
with reactive from those with nonreactive pulmonary
circulation. All patients with diffuse form of systemic
sclerosis did not respond to iNO. On the other hand, all but
one patient with limited type of the disease were reactive
(Table 1; p<0.05). Furthermore, the presence of pulmonary
fibrosis on high-resolution computerized tomography
(HRCT) scans was more frequent in nonreactive subjects
(67% of patients) than in the reactive group (40% of
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Fig. 1 Right ventricle systolic pressure in 14 patients with RVSP
>45 mmHg, before and during iNO test. Test was positive in five
patients (continuous lines), in nine pulmonary circulation was not
reactive to iNO (dashed lines)
10
12
14
16
18
normal RVSP iNO reactive iNO non-reactive
before iNO
during iNO
[cm/s] 
x 
# 
# 
Fig. 2 Right ventricle systolic function (tricuspid systolic velocity) in
patients with normal right ventricle systolic pressure (RVSP) and in
patients with elevated RVSP reactive and nonreactive to iNO, #p<0.05
according to the values in the patients with normal RVSP, xp<0.01
according to the value before iNO test
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patients, p<0.05). The single male in this group was not
reactive. Age of the patients, duration of the disease, RVSP,
and spirometry results had no influence on the reactivity of
pulmonary circulation to iNO (Table 1).
Discussion
The main finding of the study includes the influence of
increased right ventricle afterload due to elevation of
pulmonary artery systolic pressure on right ventricle
systolic dysfunction in SSc patients. Decrease of pulmonary
pressure during inhaled NO test leads to right ventricle
systolic function improvement.
Pulmonary hypertension is a devastating vascular
complication of a number of connective tissue diseases,
first of all systemic sclerosis, where it has a dramatic
impact on the clinical course and overall survival. PH and
pulmonary fibrosis are the most common cause of death in
patients afflicted with SSc [11]. Although remarkable
advances have been made to elucidate pathogenesis of
idiopathic PH and in consequence to develop disease-
targeted therapies, the response to this therapy in SSc-
related PH is suboptimal and survival remains poor [12].
While in diffuse SSc, PH is usually secondary to interstitial
lung disease, it occurs commonly also in patients with
limited form of SSc [13]. Due to clinical similarity, the
results of therapeutic trials in idiopathic PH are used to
Fig. 3 Influence of iNO on right ventricle IVRT. IVRT measured by
TDE represents the distance between the end of systolic S wave and
the beginning of early diastolic E wave. a In a patient with elevated
pulmonary artery systolic pressure (57 mmHg), IVRT is prolonged
(>100 ms). b During iNO test, pulmonary pressure decreases
(32 mmHg) with IVRT normalization to <30 ms in this patient
Δ S [cm/s]
Δ RVSP [mmHg]
ΔS = 0,089 ΔRVSP – 0,15
Fig. 4 Correlation between
right ventricle systolic pressure
(RVSP) decrease (ΔRVSP)
and tricuspid systolic velocity
increase (ΔS) during iNO test
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guide treatment in SSc–PH [12]. On the other hand, SSc
patient population is becoming an important study group
for the evaluation of novel pulmonary vasodilator
therapies. Despite the similarities between idiopathic
and SSc-related PH, pathologic findings may vary
reflecting different pathogenetic mechanisms.
Inhaled NO is a selective pulmonary vasodilator that acts
preferentially on ventilated regions. Because it is rapidly
inactivated by hemoglobin, this mode of administration
produces little, if any, direct effect on the systemic
vasculature. There is no ventilation-perfusion mismatching
or hypotension, which often limit the use of conventional
nonselective vasodilators [14]. In the present study, the dose
of iNO (40 ppm) appeared safe and did not result in
systemic hypotension in any patient.
We showed that the type of the disease and the presence
of fibrosis on HRCT strongly differentiated patients with
reactive from those with nonreactive pulmonary circulation.
Pulmonary fibrosis in diffuse SSc patients leads to the
persistent elevation of pulmonary artery systolic pressure.
This condition makes the prognosis of the patients particularly
grim [15]. The elevation of pulmonary artery pressure in
limited SSc may result, among others, from vasospasm due
to, e.g., decreased production of endogenous inducible NO
synthase [16, 17]. Thus, the vasospasm and pulmonary
resistance in limited SSc may react to iNO. This finding may
help to select patients who may benefit from treatment with
vasodilators. The therapy aimed at decreasing the pulmonary
pressure is of utmost importance, not only in a long-term
prognosis, but also in a short term, where even slight
elevation of pulmonary resistance (pulmonary pressures in
the upper normal range) leads to a significantly decreased
exercise capacity [18].
Tissue Doppler echocardiography gives the possibility to
assess systolic and diastolic right ventricle function that is
not attainable with standard echocardiography [6]. Recent
studies in SSc patients based on TDE showed both systolic
and diastolic right ventricle dysfunction [6, 7]. We showed
impaired right ventricle systolic function in the patients
with elevated RVSP as compared to the patients with
normal pulmonary pressure. However, in patients with
reactive pulmonary circulation, a significant increase in
right ventricle systolic function during iNO test was
demonstrated. On the contrary, in nonreactive patients,
systolic function of the right ventricle remained unchanged.
A drop in pulmonary systolic pressure during iNO test
highly correlated with tricuspid annulus systolic velocity
increase (Fig. 4).
The IVRT of the right ventricle is a sensitive marker of
pulmonary pressure elevation [10, 19]. The normalization
of IVRT during iNO test confirms the decrease in
pulmonary systolic pressures and improvement in RV
function in reactive patients.
There are few data from literature concerning the RV
function improvement during iNO test. The results based on
right-heart catheterization presented by Sitbone [4] confirmed
increase in right ventricle stroke volume in iNO responders.
With regard to the reactivity of RV function to iNO test, we
may expect the improvement of RV function during the
treatment focused on the decrease in pulmonary pressure
[20]. It was shown that tricuspid annulus systolic velocity
above 12 cm/s predicts the lower incidence of readmission
to hospital and improves prognosis [7]. In SSc patients
reactive to iNO, therapy of right-heart failure should then
be focused on decreasing pulmonary resistance. The
increase in tricuspid annulus systolic velocity >12 cm/s
should be our aim while lowering pulmonary artery
pressure in right-heart failure SSc patients.
Limitations of the study
Although the study was performed in 60 SSc patients, the
main findings concerning the reactivity of pulmonary
circulation to iNO are based on the examination of limited
group of 14 patients with elevated pulmonary artery
Reactive Nonreactive p Value
Age (years) 53.2±11.8 57.7±3.3 ns
Gender 5 (100%) females 8 (89%) females ns
0 (0%) males 1 (11%) male
Time of the disease (years) 4.5±1.9 3.5±1.4 ns
Type of the disease 5 (100%) limited 1 (11%) limited <0.05
0 (0%) diffuse 8 (89%) diffuse
Right ventricle systolic pressure (mmHg) 51.6±3.7 53.5±5.7 ns
Spirometry–FVC (liters) 2.71±0.9 2.51±0.8 ns
Spirometry–FEV1 (liters) 2.26±0.8 2.09±0.7 ns
Pulmonary fibrosis in HRCT 2 (40%) present 6 (67%) present <0.05
3 (60%) absent 3 (33%) absent
Table 1 Clinical, echocardio-
graphic, spirometric, and
tomographic data obtained
in patients with pulmonary
circulation reactive and
nonreactive to iNO
FVC forced vital capacity,
FEV1 forced first–second
expiratory volume,
HRCT high-resolution
computerized tomography
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systolic pressure. All measurements were performed non-
invasively, without direct hemodynamic assessment. The
group of patients evaluated during the study requires long-
term follow up.
Conclusions
Pulmonary circulation reactive to inhaled NO was found
predominantly in limited type of systemic sclerosis. The
presence of pulmonary fibrosis typical for diffuse SSc was
more frequent in nonreactive subjects. Increased right
ventricle afterload due to elevated pulmonary artery systolic
pressure is an important factor influencing right ventricle
systolic dysfunction in SSc patients. Decrease of pulmonary
pressure during inhaled NO test leads to right ventricle
systolic function improvement. This suggests that the
therapy of right-heart failure in reactive patients should be
aimed if possible on the decrease in pulmonary resistance.
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